Analysts Set argenx SE (NASDAQ:ARGX) PT at $658.39

argenx SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-two ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $658.39.

Several equities research analysts have issued reports on the company. Guggenheim raised their price target on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. JMP Securities increased their price target on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Wedbush reaffirmed an “outperform” rating and issued a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Truist Financial reissued a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Raymond James reaffirmed a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a report on Thursday, October 10th.

argenx Price Performance

Shares of ARGX opened at $640.52 on Friday. The company has a market cap of $38.67 billion, a PE ratio of -727.86 and a beta of 0.59. The firm has a 50-day moving average of $620.19 and a 200-day moving average of $557.36. argenx has a one year low of $349.86 and a one year high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the previous year, the business earned ($1.25) earnings per share. Analysts expect that argenx will post 2.17 earnings per share for the current year.

Institutional Investors Weigh In On argenx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after buying an additional 21 shares in the last quarter. Profund Advisors LLC grew its position in argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock valued at $418,000 after acquiring an additional 28 shares during the last quarter. Raymond James Trust N.A. raised its stake in argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. Wealth Alliance lifted its holdings in shares of argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after acquiring an additional 29 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its stake in shares of argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock valued at $286,000 after purchasing an additional 43 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.